Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Payables of $163.5 million for Q4 2025, up 57.29% on a QoQ basis from $103.9 million in Q4 2024, and up 57.29% year-over-year from $103.9 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Payables data on file, last reported at $163.5 million in Q4 2025.

  • In Q4 2025, Payables rose 57.29% year-over-year to $163.5 million; the TTM figure through Dec 2025 stood at $163.5 million (up 57.29% YoY), while the FY2025 annual figure was $163.5 million, up 57.29% from the prior year.
  • Payables climbed to $163.5 million in Q4 2025, from $103.9 million in the prior quarter.
  • Across five years, Payables topped out at $163.5 million in Q4 2025 and bottomed at $22.0 million in Q4 2023.
  • A 3-year average of $96.5 million and a median of $103.9 million in 2024 frame the typical range for Payables.
  • Annual changes were most pronounced in 2024 — Payables soared 372.3% — and 2025, when it surged 57.29%.
  • Year by year, Payables stood at $22.0 million in 2023, then soared by 372.3% to $103.9 million in 2024, then surged by 57.29% to $163.5 million in 2025.
  • The last three Payables figures came in at $163.5 million (Q4 2025), $103.9 million (Q4 2024), and $22.0 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Payables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 300,549.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1.05 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 83.00 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 10.62 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 8.69 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 489.30 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.03 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 126.63 Mn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 163.46 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 163.46 Mn
Dec 31, 2024 103.92 Mn
Dec 31, 2023 22.00 Mn